Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) significantly reduce HbA1c levels and body weight in patients with type 2 diabetes and obesity, with efficacy increasing from single agonists to dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists.

GLP-1 based medications (single, dual, and triple agonists) are highly effective for treating type 2 diabetes and obesity. They work by mimicking hormones that regulate blood sugar and appetite. Newer dual and triple agonists (like Tirzepatide and Retatrutide) show greater improvements in blood sugar and weight loss than older single-agonist drugs. Treatment is typically chronic, as stopping the medication often leads to weight regain. Options include weekly or daily injections, and some oral formulations are available for those who prefer to avoid needles. Consult a doctor to determine the best agent and dose for your specific health profile.

Combining amylin receptor agonist (cagrilintide) with GLP-1 RA (semaglutide) results in greater weight reduction than semaglutide monotherapy.

Combining cagrilintide 2.4 mg and semaglutide 2.4 mg, both injected once weekly, leads to 17.1% body weight loss over 20 weeks, which is significantly better than semaglutide alone (9.8%).

Resistance training load (intensity) and weekly frequency impact muscular strength gains, whereas volume (number of sets) influences both strength and hypertrophy.

To maximize strength, prioritize higher loads and higher training frequencies. To maximize muscle size, prioritize higher training volumes (more sets per muscle group). These variables are distinct drivers for different adaptations.

High levels of physical inactivity and consumption of sugary beverages are primary drivers of obesity prevalence in Saudi Arabia, with inactive individuals showing significantly lower risk reduction compared to active males.

Focus on reducing sugary beverage intake and increasing physical activity, even in small amounts, as inactivity is a major driver of obesity in this region.

Produce prescription programs, which provide financial incentives for low-income individuals to purchase fruits and vegetables, significantly improve fruit and vegetable intake, reduce food insecurity, and yield clinically relevant improvements in glycated hemoglobin, blood pressure, and BMI for adults with poor cardiometabolic health.

If you or your family are struggling to afford fresh produce, look for local 'produce prescription' programs often offered through community health centers or clinics. These programs provide vouchers or cards to buy fruits and vegetables, often for free or at a reduced cost, which can help lower blood pressure and blood sugar while improving overall diet quality.

Combining incretin-mimetic drug therapy with resistance training and adequate protein intake minimizes skeletal muscle loss and preserves metabolic health.

To keep your muscle while losing weight on GLP-1 drugs, you must lift weights at least twice a week and eat enough protein (aim for 1.0-1.5g per kg of your goal weight). This combination is the only way to ensure the weight you lose comes from fat, not muscle.

Antiobesity medications (AOMs) such as semaglutide and tirzepatide significantly reduce energy intake and appetite, necessitating a shift in nutritional focus from caloric restriction alone to ensuring nutrient density and adequate protein intake to prevent lean mass loss and deficiencies.

When starting semaglutide or tirzepatide, your appetite will drop significantly. Do not just eat less; eat smarter. Prioritize protein (aim for 60-75g daily or up to 1.5g per kg of body weight) and nutrient-dense foods like vegetables, lean meats, and whole grains. This protects your muscle and ensures you get necessary vitamins despite eating smaller portions.

Adequate dietary protein intake (60-75 g/day or up to 1.5 g/kg body weight/day) is critical during AOM therapy to preserve lean body mass and prevent complications like weakness and edema, especially in older adults.

To keep your muscles while losing weight, aim for 60-75 grams of protein daily, or up to 1.5 grams per kilogram of your body weight. Eat high-protein foods first at each meal. This is especially important if you are older to prevent falls and muscle loss.

Excessive consumption of free sugars, particularly from sugar-sweetened beverages (SSBs) and high-fructose corn syrup, negatively impacts human health by promoting obesity, type 2 diabetes, cardiovascular disease, and cognitive impairment through mechanisms like insulin resistance, de novo lipogenesis, and neuroinflammation.

To protect your metabolic and cognitive health, prioritize reducing free sugars, especially from sugar-sweetened beverages and high-fructose corn syrup. Aim for less than 5% of your daily calories from added sugars (approx. 25g for women, 36g for men, per AHA/WHO). Focus on whole food sources of carbohydrates (vegetables, whole grains, whole fruits) which provide fiber and nutrients, rather than isolated sugars. This helps mitigate risks of insulin resistance, liver fat accumulation, and cognitive decline.

Achieving a weight loss of ≥5% is clinically meaningful for improving cardiometabolic risk factors and is the threshold for FDA approval of anti-obesity medications, though greater losses (≥10-15%) are required for remission of conditions like type 2 diabetes and NASH.

Aim for a 5% weight loss as a primary, achievable goal to significantly improve your heart health and metabolic markers. If you have specific conditions like Type 2 Diabetes or NASH, discuss with your doctor if a higher target (10-15%) is needed for remission, but do not let the higher target discourage you from starting with the 5% goal, which brings substantial health benefits.

Lifestyle interventions, specifically a Mediterranean diet and 150-300 minutes of moderate or 75-150 minutes of vigorous exercise weekly, are recommended to induce weight loss and improve cardiovascular risk factors in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Adopt a Mediterranean-style diet focused on reducing total calories, saturated fats, and processed sugars while increasing intake of fish, vegetables, nuts, and fiber. Combine this with at least 150 minutes of moderate exercise (like brisk walking) or 75 minutes of vigorous exercise per week. Aim for a 5-10% reduction in body weight to significantly improve liver health and cardiovascular risk.

High-dose GLP-1 receptor agonists (specifically semaglutide 2.4 mg) combined with lifestyle interventions produce significant, sustainable weight loss (-14.9% body weight) and improved glycemic control in patients with diabesity, making them superior to insulin and other antidiabetic agents regarding weight management.

If you have both diabetes and obesity, ask your doctor about GLP-1 agonists like semaglutide (2.4 mg). This treatment, combined with diet and exercise changes, has been shown to help patients lose nearly 15% of their body weight over 68 weeks while also controlling blood sugar. It is often more effective for weight loss than insulin, which tends to cause weight gain. Be aware that you might experience some nausea or vomiting at first, but these symptoms usually go away, and the long-term health benefits are significant.

Weight loss of 15 kg can induce remission of Type 2 Diabetes in approximately 70% of individuals, and even smaller weight losses (5 kg) improve insulin sensitivity and glycemic control, highlighting the primacy of lifestyle interventions in diabesity management.

Losing weight is the most powerful tool for managing Type 2 Diabetes. Losing 15 kg can put diabetes into remission for about 70% of people. Even losing 5 kg improves how your body uses insulin. To succeed, combine dietary changes (like Mediterranean or low-carb diets) with regular exercise. Focus on stepwise, realistic goals rather than quick fixes to ensure long-term success.

Lifestyle therapy, specifically smoking cessation, is the single most important component of lifestyle management for patients with cardiorenal and metabolic diseases.

Stop smoking. It is the single most impactful lifestyle change you can make for your heart, kidneys, and metabolic health. Ask your doctor for support to help you quit.

Adequate sleep (7-9 hours nightly) is a critical lifestyle factor that decreases risks of insulin resistance, hypertension, hyperglycemia, dyslipidemia, and inflammation.

Prioritize getting 7-9 hours of sleep each night. Poor sleep directly worsens your blood sugar, blood pressure, and inflammation.

Weight reduction in individuals with obesity and obstructive sleep apnea (OSA) significantly reduces the Apnea-Hypopnea Index (AHI), with a 20% BMI reduction associated with a 57% AHI reduction, though the incremental benefit diminishes beyond this threshold.

If you have OSA and are overweight, losing weight is one of the most effective treatments available. Losing 20% of your body weight can reduce your sleep apnea severity by more than half. However, be aware that the biggest improvements happen in the first stages of weight loss; losing even more weight still helps, but the gains become smaller. Don't let the diminishing returns stop you—every bit of weight loss contributes to better sleep health.

Progressing resistance training by increasing repetitions while keeping load constant produces similar muscle hypertrophy and strength gains as progressing by increasing load while keeping repetitions constant over an 8-week period.

You do not need to add weight to the bar every week to keep building muscle. If you are stuck at a certain weight, focus on doing more repetitions with that same weight. As long as you are pushing close to failure, increasing your reps is just as effective for building muscle and strength as increasing the weight itself. This gives you a flexible way to progress, especially when you hit a plateau with adding weight.

Creatine supplementation combined with resistance training produces a small but statistically significant increase in regional skeletal muscle hypertrophy (measured by direct imaging like MRI/ultrasound) compared to resistance training alone.

If you are lifting weights, adding creatine (3-5g daily or 0.1g/kg) will likely help you build a small amount of extra muscle compared to lifting alone. The effect is small, not massive, but it is real and supported by direct imaging studies. It works for both young and older adults, though the benefit may be slightly larger in younger individuals.

Adherence to a Mediterranean diet reduces cardiometabolic risk by improving lipid profiles, lowering blood pressure, and enhancing insulin sensitivity.

Adopt a Mediterranean-style eating pattern by prioritizing plant-based foods, healthy fats like olive oil, and moderate protein from fish and poultry. This approach is linked to lower risks of heart disease and stroke. Focus on long-term adherence rather than strict calorie counting.

The Mediterranean diet reduces visceral adiposity and insulin resistance, key drivers of metabolic syndrome.

Focus on reducing visceral fat by following a Mediterranean diet rich in fiber and healthy fats. This helps improve insulin sensitivity and reduces the risk of metabolic syndrome, even if total body weight changes are gradual.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) produce the greatest weight loss among anti-diabetic medications, with effects classified as strong (>5% reduction), whereas DPP-4 inhibitors and alpha-glucosidase inhibitors (acarbose) produce only mild or neutral effects.

If you have Type 2 Diabetes and struggle with weight loss, GLP-1 receptor agonists (like liraglutide or semaglutide) are currently the most effective pharmacological option for reducing body weight, significantly outperforming older drugs like DPP-4 inhibitors or acarbose. While these drugs may cause initial gastrointestinal side effects, their ability to produce strong weight loss (>5%) makes them a superior choice for managing obesity in diabetic patients compared to weight-neutral or weight-gain-inducing alternatives like sulfonylureas or insulin.

GLP-1 receptor agonists (GLP-1 RAs) promote weight loss and improve glycemic control through multiple mechanisms including increased satiety, slowed gastric emptying, and enhanced insulin secretion, with semaglutide 2.4 mg showing the highest efficacy.

GLP-1 receptor agonists like semaglutide are highly effective for weight loss and blood sugar control. Semaglutide 2.4 mg taken once weekly (either orally or by injection) resulted in an average loss of 15.3 kg over 68 weeks in clinical trials. This is significantly more effective than placebo. These drugs work by increasing satiety, slowing digestion, and improving insulin function. They are suitable for adults with obesity or type 2 diabetes.

Tirzepatide 15 mg provides superior HbA1c reduction and bodyweight loss compared to other GLP-1RA-based therapies, including high-dose GLP-1RA and GLP-1RA plus basal insulin fixed-ratio combinations, without increasing the risk of hypoglycemia.

For patients with type 2 diabetes seeking maximum glycemic control and weight loss, tirzepatide 15 mg is the most effective GLP-1RA-based therapy available, outperforming high-dose GLP-1RAs and insulin combinations without increasing hypoglycemia risk.

Lifestyle interventions achieving 7-10% body weight loss are effective in resolving nonalcoholic steatohepatitis (NASH) and regressing fibrosis in patients with metabolic-associated fatty liver disease (MAFLD).

To reverse liver inflammation and fibrosis, you need to lose 7-10% of your body weight through diet and exercise. Losing more than 10% can even reverse scarring (fibrosis). The hardest part is sticking with it, as most people fail to reach these targets. Combine a calorie-restricted diet (like the Mediterranean diet) with 150-300 minutes of moderate exercise per week.